VASCULAR RESEARCH NETWORK BVBA: what changed
VASCULAR RESEARCH NETWORK BVBA
Largest movements
- Receivables within one year -€3,525
down €3,525 (-77.9%), from €4,522 to €997
of which Trade receivables: -€3,525
- Profit (loss) carried forward -€11,096
down €11,096 (-6.3%), from -€177,177 to -€188,273
- Accrued charges and deferred income +€10,051
up €10,051 (+19.7%), from €51,014 to €61,065
- Trade debts -€2,632
down €2,632 (-100%), from €2,632 to €0
- Other operating charges +€3,872
new in 2025: €3,872
- Gross operating margin +€3,613
new in 2025: €3,613
- Financial charges +€1,265
up €1,265 (+13.2%), from €9,572 to €10,837
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €45,069 | €41,392 | -€3,677 | -8.2% |
| Current assets | 29/58 | €45,069 | €41,392 | -€3,677 | -8.2% |
| Amounts receivable within one year | 40/41 | €4,522 | €997 | -€3,525 | -77.9% |
| Trade receivables | 40 | €3,525 | €0 | -€3,525 | -100% |
| Other amounts receivable | 41 | €997 | €997 | = | 0.0% |
| Cash at bank and in hand | 54/58 | €40,199 | €40,395 | +€196 | +0.5% |
| Deferred charges and accrued income | 490/1 | €348 | €0 | -€348 | -100% |
| Total equity and liabilities | 10/49 | €45,069 | €41,392 | -€3,677 | -8.2% |
| Equity | 10/15 | -€158,577 | -€169,673 | -€11,096 | -7.0% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€177,177 | -€188,273 | -€11,096 | -6.3% |
| Amounts payable | 17/49 | €203,646 | €211,065 | +€7,419 | +3.6% |
| Amounts payable after more than one year | 17 | €150,000 | €150,000 | = | 0.0% |
| Other amounts payable | 178/9 | €150,000 | €150,000 | = | 0.0% |
| Amounts payable within one year | 42/48 | €2,632 | €0 | -€2,632 | -100% |
| Trade debts | 44 | €2,632 | €0 | -€2,632 | -100% |
| Suppliers | 440/4 | €2,632 | €0 | -€2,632 | -100% |
| Accrued charges and deferred income | 492/3 | €51,014 | €61,065 | +€10,051 | +19.7% |
| Other operating charges | 640/8 | - | €3,872 | +€3,872 | |
| Gross operating margin | 9900 | - | €3,613 | +€3,613 | |
| Operating profit (loss) | 9901 | - | -€259 | -€259 | |
| Financial charges | 65/66B | €9,572 | €10,837 | +€1,265 | +13.2% |
| Recurring financial charges | 65 | €9,572 | €10,837 | +€1,265 | +13.2% |
| Profit (loss) for the period before taxes | 9903 | -€9,572 | -€11,096 | -€1,524 | -15.9% |
| Profit (loss) for the period | 9904 | -€9,572 | -€11,096 | -€1,524 | -15.9% |
| Profit (loss) for the period to be appropriated | 9905 | -€9,572 | -€11,096 | -€1,524 | -15.9% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 2 November 2026 via checked.be.